CaPre omega-3 phospholipids: Phase II ongoing

On Dec. 17, 2012, Acasti said an independent review committee recommended continuation of the double-blind, placebo-controlled, Canadian Phase II TRIFECTA trial of CaPre based on an interim analysis o...